GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III StudyZacks Investment Research • 11/20/24
GSK trial shows promising results for treatment of persistent itch in rare liver diseaseProactive Investors • 11/19/24
GSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)Seeking Alpha • 11/15/24
GSK at two-year low, drug firms hit on vaccine sceptic US health appointmentProactive Investors • 11/15/24
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine SalesZacks Investment Research • 10/30/24
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024Benzinga • 10/30/24
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVYPRNewsWire • 10/28/24